Shares of BKV Corp—a unit of Thailand’s billionaire Vongkusolkit family's Banpu—closed flat in its trading debut on Thursday ...

Obesity-drug developer BioAge Labs Inc. gained about 20% after its initial public offering on Thursday, while natural-gas ...

The U.S. IPO market has bounced back strongly in 2024 after a nearly two-year dry spell, driven by receding recession fears ...

Obesity-drug developer BioAge Labs Inc. gained nearly 30% after its initial public offering on Thursday, while natural-gas producer BKV Inc.'s rose about 3% over its $18 IPO price. BioAge (BIOA) stock ...

BKV shares rose by 3.1% on their New York Stock Exchange debut on Thursday. This gives the U.S. Natural Gas Producer a market cap of $1.56 Billion.

(Reuters) -Shares of BKV rose 3.1% in their debut on the New York Stock Exchange on Thursday, giving the U.S. natural gas ...

Japanese conglomerate Mitsubishi will acquire a 10% stake in a Sarawak natural gas liquefaction facility run by Malaysian state energy firm Petroliam Nasional for a ten-year period by the end of 2024, ...

Texas-based Barnett Shale driller BKV Inc. priced below the estimated range, while obesity-drug developer BioAge Labs Inc. priced midrange ahead of their first day of trading on Thursday. As the ...

Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead ...

Natural gas producer BKV Corp said on Wednesday it had raised $270 million in its U.S. initial public offering.

BioAge Labs (BIOA), which is developing a drug to augment popular weight-loss medications such as Wegovy and Zepbound, has upsized its proposed IPO. Read more here.

BKV Corp. priced its common shares at $18 each after and will begin trading on Sept. 26, about two years after the Denver ...